Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
J. Hannemann,
Y. Erim,
E. Morawa,
L. Jerg-Bretzke,
P. Beschoner,
F. Geiser,
N. Hiebel,
K. Weidner and
S. Steudte-Schmiedgen,
"The impact of the COVID-19 pandemic on the mental health of medical staff considering the interplay of pandemic burden and psychosocial resources-A rapid systematic review",
PLoS One,
vol. 17,
no. 2,
pp. e0264290,
2022.
| DOI: | 10.1371/journal.pone.0264290 |
A. Schreiber,
D. Viemann,
J. Schöning,
S. Schloer,
A. Mecate Zambrano and
e. a. Brunotte,
"The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses",
Cell Mol Life Sci,
vol. 79,
pp. 65,
2022.
| DOI: | 10.1007/s00018-021-03917-x |
P. R. Wratil,
M. Stern,
A. Priller and
et al,
"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern",
Nat Med,
2022.
| DOI: | 10.1038/s41591-022-01715-4 |
J. Kamp,
L. Neubert and
et al,
"Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19",
Int J Mol Sci,
vol. 23,
2022.
| DOI: | 10.3390/ijms23031583 |
[eng]
J. C. Kamp,
L. Neubert,
H. Stark,
C. Werlein,
J. Fuge,
A. Haverich,
A. Tzankov,
K. Steinestel,
J. Friemann,
P. Boor,
K. Junker,
M. M. Hoeper,
T. Welte,
F. Laenger,
M. P. Kuehnel and
D. D. Jonigk,
"Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19",
International Journal of Molecular Sciences,
vol. 23,
no. 3,
pp. 1583,
Jan.
2022.
Abstract:
(1) Background: In COVID-19 survivors there is an increased prevalence of pulmonary fibrosis of which the underlying molecular mechanisms are poorly understood; (2) Methods: In this multicentric study, n = 12 patients who succumbed to COVID-19 due to progressive respiratory failure were assigned to an early and late group (death within ≤7 and \textgreater7 days of hospitalization, respectively) and compared to n = 11 healthy controls; mRNA and protein expression as well as biological pathway analysis were performed to gain insights into the evolution of pulmonary fibrogenesis in COVID-19; (3) Results: Median duration of hospitalization until death was 3 (IQR25-75, 3-3.75) and 14 (12.5-14) days in the early and late group, respectively. Fifty-eight out of 770 analyzed genes showed a significantly altered expression signature in COVID-19 compared to controls in a time-dependent manner. The entire study group showed an increased expression of BST2 and IL1R1, independent of hospitalization time. In the early group there was increased activity of inflammation-related genes and pathways, while fibrosis-related genes (particularly PDGFRB) and pathways dominated in the late group; (4) Conclusions: After the first week of hospitalization, there is a shift from pro-inflammatory to fibrogenic activity in severe COVID-19. IL1R1 and PDGFRB may serve as potential therapeutic targets in future studies.
| DOI: | 10.3390/ijms23031583 |
Abstract:
(1) Background: In COVID-19 survivors there is an increased prevalence of pulmonary fibrosis of which the underlying molecular mechanisms are poorly understood; (2) Methods: In this multicentric study, n = 12 patients who succumbed to COVID-19 due to progressive respiratory failure were assigned to an early and late group (death within ≤7 and \textgreater7 days of hospitalization, respectively) and compared to n = 11 healthy controls; mRNA and protein expression as well as biological pathway analysis were performed to gain insights into the evolution of pulmonary fibrogenesis in COVID-19; (3) Results: Median duration of hospitalization until death was 3 (IQR25-75, 3-3.75) and 14 (12.5-14) days in the early and late group, respectively. Fifty-eight out of 770 analyzed genes showed a significantly altered expression signature in COVID-19 compared to controls in a time-dependent manner. The entire study group showed an increased expression of BST2 and IL1R1, independent of hospitalization time. In the early group there was increased activity of inflammation-related genes and pathways, while fibrosis-related genes (particularly PDGFRB) and pathways dominated in the late group; (4) Conclusions: After the first week of hospitalization, there is a shift from pro-inflammatory to fibrogenic activity in severe COVID-19. IL1R1 and PDGFRB may serve as potential therapeutic targets in future studies.
A. Wulff,
P. Biermann,
T. von Landesberger,
T. Baumgartl,
C. Schmidt,
K. Schick,
P. Waldstein,
Y. Zhu,
D. Krefting,
S. Scheithauer and
M. Marschollek,
"Tracing COVID-19 Infection Chains Within Healthcare Institutions - Another Brick in the Wall Against SARS-CoV-2",
Studies in health technology and informatics,
vol. 290,
pp. 699—703,
2022.
| DOI: | 10.3233/SHTI220168 |
C. Schug,
Y. Erim,
F. Geiser,
N. Hiebel,
P. Beschoner,
L. Jerg-Bretzke,
K. Weidner,
S. Steudte-Schmiedgen,
A. Borho,
M. Lieb and
E. Morawa,
"Vaccination willingness against COVID-19 among healthcare workers in Germany: Results from a University Medicine Network survey between November 2020 and January 2021",
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz,
vol. 65,
no. 1,
pp. 74—85,
Jan.
2022.
| DOI: | 10.1007/s00103-021-03418-6 |
| Datei: |  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458789/pdf/103_2021_Article_3418.pdf |
C. Struwe,
M. Golinski,
C. Grimm,
S. Dickel,
K. Grummich,
M. Nothacker,
S. Voigt-Radloff,
J. Meerpohl and
O. Moerer,
"Vergleich und Bewertung internationaler Leitlinien zur Behandlung schwerer Verläufe von SARS-CoV-2-Infektionen",
Dtsch Arztebl Int,
vol. 119,
pp. 23-30,
2022.
| DOI: | 10.3238/arztebl.m2022.0006 |
K. Mayer,
"Pandemic Disruptions and Transnational Care Relations: Towards Closing the “Care Gap” in International Relations Theories"
in In the Realm of Corona Normativities II, Gephart, W, Eds.
Verlag Vitorrio Klostermann,
2022.
M. Reichardt,
P. Moller Jensen,
V. Andersen Dahl,
A. Bjorholm Dahl,
M. Ackermann,
H. Shah,
F. Länger,
C. Werlein,
M. P. Kuehnel,
D. Jonigk and
T. Salditt,
"3D virtual histopathology of cardiac tissue from Covid-19 patients based on phase-contrast X-ray tomography",
eLife,
vol. 10,
pp. e71359,
Dez.
2021.
| DOI: | 10.7554/eLife.71359 |
| Datei: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747495/ |
H. Meyer,
N. Bailis and
A. Surov,
"Can the CT by-product Time to threshold be a prognostic factor in patients with acute pulmonary embolism?",
Journal of medical imaging and radiation oncology,
vol. 65,
no. 7,
pp. 846-849,
Dez.
2021.
Abstract:
Bolus tracking is applied in computed tomography pulmonary angiography. The time that it takes for contrast to reach a predefined threshold in the pulmonary artery is called time to threshold (TTT). Our purpose was to analyse possible associations between TTT and circulatory state and prognosis in patients with acute pulmonary embolism (PE). In a single-centre, retrospective study 138 patients with PE and contrast administration via peripheral venous line were included. Clinical parameters of circulatory state were arterial pH, systolic blood pressure, heart rate, sPESI score, Wells score and GENEVA score. Survival was defined as surviving the following 30 days after the PE diagnosis. Time to threshold was only weakly correlated with Fi02 (r = 0.26, P = 0.04), pH (r = -0.22, P = 0.009), venous base excess (r = -0.18, P = 0.04) and venous lactate (r = 0.21, P = 0.01). TTT did not correlate with clinical parameters/scores and mortality. There were weak associations between TTT and blood gas analysis parameters. There were no associations with clinically relevant prognosis scores and overall survival. Therefore, albeit TTT is an easily assessable parameter of CTPA, the potential use in clinical routine is limited for prognosis stratification in patients with PE.
| DOI: | 10.1111/1754-9485.13246 |
| Datei: | https://pubmed.ncbi.nlm.nih.gov/34060228/ |
Abstract:
Bolus tracking is applied in computed tomography pulmonary angiography. The time that it takes for contrast to reach a predefined threshold in the pulmonary artery is called time to threshold (TTT). Our purpose was to analyse possible associations between TTT and circulatory state and prognosis in patients with acute pulmonary embolism (PE). In a single-centre, retrospective study 138 patients with PE and contrast administration via peripheral venous line were included. Clinical parameters of circulatory state were arterial pH, systolic blood pressure, heart rate, sPESI score, Wells score and GENEVA score. Survival was defined as surviving the following 30 days after the PE diagnosis. Time to threshold was only weakly correlated with Fi02 (r = 0.26, P = 0.04), pH (r = -0.22, P = 0.009), venous base excess (r = -0.18, P = 0.04) and venous lactate (r = 0.21, P = 0.01). TTT did not correlate with clinical parameters/scores and mortality. There were weak associations between TTT and blood gas analysis parameters. There were no associations with clinically relevant prognosis scores and overall survival. Therefore, albeit TTT is an easily assessable parameter of CTPA, the potential use in clinical routine is limited for prognosis stratification in patients with PE.
A. Osterman,
M. Iglhaut,
A. Lehner,
P. Späth,
M. Stern,
H. Autenrieth,
M. Muenchhoff,
A. Graf,
S. Krebs,
H. Blum,
A. Baiker,
N. Grzimek-Koschewa,
U. Protzer,
L. Kaderali,
H. Baldauf and
O. Keppler,
"Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern",
Med Microbiol Immunol,
no. 210,
pp. 263-275,
Dez.
2021.
| DOI: | 10.1007/s00430-021-00719-0 |
[de]
S. Stillfried,
P. Boor and
D. PANDEMIcs,
"Entwicklung eines kooperativen Obduktionsnetzwerks aus Pathologie, Neuropathologie und Rechtsmedizin",
Der Pathologe,
vol. 42,
no. 2,
pp. 129—134,
Dez.
2021.
| DOI: | 10.1007/s00292-021-01004-w |
| Datei: | https://doi.org/10.1007/s00292-021-01004-w |
[en]
C. L. Walsh,
P. Tafforeau,
W. L. Wagner,
D. J. Jafree,
A. Bellier,
C. Werlein,
M. P. Kühnel,
E. Boller,
S. Walker-Samuel,
J. L. Robertus,
D. A. Long,
J. Jacob,
S. Marussi,
E. Brown,
N. Holroyd,
D. D. Jonigk,
M. Ackermann and
P. D. Lee,
"Imaging intact human organs with local resolution of cellular structures using hierarchical phase-contrast tomography",
Nature Methods,
vol. 18,
no. 12,
pp. 1532—1541,
Dez.
2021.
| DOI: | 10.1038/s41592-021-01317-x |
| Datei: | https://www.nature.com/articles/s41592-021-01317-x |
[eng]
D. Wendisch,
O. Dietrich,
T. Mari,
S. Stillfried,
I. L. Ibarra,
M. Mittermaier,
C. Mache,
R. L. Chua,
R. Knoll,
S. Timm,
S. Brumhard,
T. Krammer,
H. Zauber,
A. L. Hiller,
A. Pascual-Reguant,
R. Mothes,
R. D. Bülow,
J. Schulze,
A. M. Leipold,
S. Djudjaj,
F. Erhard,
R. Geffers,
F. Pott,
J. Kazmierski,
J. Radke,
P. Pergantis,
K. Baßler,
C. Conrad,
A. C. Aschenbrenner,
B. Sawitzki,
M. Landthaler,
E. Wyler,
D. Horst,
D. C. O. I. (DeCOI),
S. Hippenstiel,
A. Hocke,
F. L. Heppner,
A. Uhrig,
C. Garcia,
F. Machleidt,
S. Herold,
S. Elezkurtaj,
C. Thibeault,
M. Witzenrath,
C. Cochain,
N. Suttorp,
C. Drosten,
C. Goffinet,
F. Kurth,
J. L. Schultze,
H. Radbruch,
M. Ochs,
R. Eils,
H. Müller-Redetzky,
A. E. Hauser,
M. D. Luecken,
F. J. Theis,
C. Conrad,
T. Wolff,
P. Boor,
M. Selbach,
A. Saliba and
L. E. Sander,
"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis",
Cell,
vol. 184,
no. 26,
pp. 6243—6261.e27,
Dez.
2021.
| DOI: | 10.1016/j.cell.2021.11.033 |
[en]
M. Witkowski,
C. Tizian,
M. Ferreira-Gomes,
D. Niemeyer,
T. C. Jones,
F. Heinrich,
S. Frischbutter,
S. Angermair,
T. Hohnstein,
I. Mattiola,
P. Nawrath,
S. McEwen,
S. Zocche,
E. Viviano,
G. A. Heinz,
M. Maurer,
U. Kölsch,
R. L. Chua,
T. Aschman,
C. Meisel,
J. Radke,
B. Sawitzki,
J. Roehmel,
K. Allers,
V. Moos,
T. Schneider,
L. Hanitsch,
M. A. Mall,
C. Conrad,
H. Radbruch,
C. U. Duerr,
J. A. Trapani,
E. Marcenaro,
T. Kallinich,
V. M. Corman,
F. Kurth,
L. E. Sander,
C. Drosten,
S. Treskatsch,
P. Durek,
A. Kruglov,
A. Radbruch,
M. Mashreghi and
A. Diefenbach,
"Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells",
Nature,
vol. 600,
no. 7888,
pp. 295—301,
Dez.
2021.
| DOI: | 10.1038/s41586-021-04142-6 |
| Datei: | https://www.nature.com/articles/s41586-021-04142-6 |
[de]
S. Berezowska,
P. Boor,
D. Jonigk and
V. Tischler,
"Update Thoraxpathologie 2021 – Bericht der Arbeitsgemeinschaft",
Der Pathologe,
vol. 42,
no. 2,
pp. 199—202,
Dez.
2021.
| DOI: | 10.1007/s00292-021-00991-0 |
| Datei: | https://doi.org/10.1007/s00292-021-00991-0 |
[en]
D. M. Smadja,
S. J. Mentzer,
M. Fontenay,
M. A. Laffan,
M. Ackermann,
J. Helms,
D. Jonigk,
R. Chocron,
G. B. Pier,
N. Gendron,
S. Pons,
J. Diehl,
C. Margadant,
C. Guerin,
E. J. M. Huijbers,
A. Philippe,
N. Chapuis,
P. Nowak-Sliwinska,
C. Karagiannidis,
O. Sanchez,
P. Kümpers,
D. Skurnik,
A. M. Randi and
A. W. Griffioen,
"COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects",
Angiogenesis,
vol. 24,
no. 4,
pp. 755—788,
Nov.
2021.
| DOI: | 10.1007/s10456-021-09805-6 |
| Datei: | https://doi.org/10.1007/s10456-021-09805-6 |
[en]
M. Lehmann,
K. Allers,
C. Heldt,
J. Meinhardt,
F. Schmidt,
Y. Rodriguez-Sillke,
D. Kunkel,
M. Schumann,
C. Böttcher,
C. Stahl-Hennig,
S. Elezkurtaj,
C. Bojarski,
H. Radbruch,
V. M. Corman,
T. Schneider,
C. Loddenkemper,
V. Moos,
C. Weidinger,
A. A. Kühl and
B. Siegmund,
"Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells",
Mucosal Immunology,
vol. 14,
no. 6,
pp. 1381—1392,
Nov.
2021.
| DOI: | 10.1038/s41385-021-00437-z |
| Datei: | https://www.sciencedirect.com/science/article/pii/S1933021922002318 |
[en]
B. Ondruschka,
F. Heinrich,
M. Lindenmeyer,
C. Edler,
D. Möbius,
J. Czogalla,
A. Heinemann,
F. Braun,
M. Aepfelbacher,
M. Lütgehetmann and
T. B. Huber,
"Multiorgan tropism of SARS-CoV-2 lineage B.1.1.7",
International Journal of Legal Medicine,
vol. 135,
no. 6,
pp. 2347—2349,
Nov.
2021.
| DOI: | 10.1007/s00414-021-02691-z |
| Datei: | https://doi.org/10.1007/s00414-021-02691-z |
R. Rubio-Acero,
J. Beyerl,
M. Muenchhoff,
M. Roth,
N. Castelletti,
I. Paunovic,
K. Radon,
B. Springer,
C. Nagel,
B. Boehm,
M. Böhmer,
A. Graf,
H. Blum,
S. Krebs,
O. Keppler,
A. Osterman,
Z. Khan,
M. Hoelscher,
A. Wieser and
on behalf of the KoCo19-Study Group,
"Spatially resolved qualified sewage spot sampling to track SARS-CoV-2 dynamics in Munich - One year of experience",
Sci Total Environ,
no. 797,
pp. 149031,
Nov.
2021.
| DOI: | 10.1016/j.scitotenv.2021.149031 |
[en]
J. Wenzel,
J. Lampe,
H. Müller-Fielitz,
R. Schuster,
M. Zille,
K. Müller,
M. Krohn,
J. Körbelin,
L. Zhang,
Ü. Özorhan,
V. Neve,
J. U. G. Wagner,
D. Bojkova,
M. Shumliakivska,
Y. Jiang,
A. Fähnrich,
F. Ott,
V. Sencio,
C. Robil,
S. Pfefferle,
F. Sauve,
C. F. F. Coêlho,
J. Franz,
F. Spiecker,
B. Lembrich,
S. Binder,
N. Feller,
P. König,
H. Busch,
L. Collin,
R. Villaseñor,
O. Jöhren,
H. C. Altmeppen,
M. Pasparakis,
S. Dimmeler,
J. Cinatl,
K. Püschel,
M. Zelic,
D. Ofengeim,
C. Stadelmann,
F. Trottein,
R. Nogueiras,
R. Hilgenfeld,
M. Glatzel,
V. Prevot and
M. Schwaninger,
"The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells",
Nature Neuroscience,
vol. 24,
no. 11,
pp. 1522—1533,
Nov.
2021.
| DOI: | 10.1038/s41593-021-00926-1 |
| Datei: | https://www.nature.com/articles/s41593-021-00926-1 |
[en]
S. Gerlach,
M. Neidhardt,
T. Weiß,
M. Laves,
C. Stapper,
M. Gromniak,
I. Kniep,
D. Möbius,
A. Heinemann,
B. Ondruschka and
A. Schlaefer,
"Needle insertion planning for obstacle avoidance in robotic biopsy",
Current Directions in Biomedical Engineering,
vol. 7,
no. 2,
pp. 779—782,
Okt.
2021.
| DOI: | 10.1515/cdbme-2021-2199 |
| Datei: | https://www.degruyter.com/document/doi/10.1515/cdbme-2021-2199/html |
F. Heinrich,
M. F. Nentwich,
E. Bibiza-Freiwald,
D. Nörz,
K. Roedl,
M. Christner,
A. Hoffmann,
F. Olearo,
S. Kluge,
M. Aepfelbacher,
D. Wichmann,
M. Lütgehetmann and
S. Pfefferle,
"SARS-CoV-2 Blood RNA Load Predicts Outcome in Critically Ill COVID-19 Patients",
Open Forum Infectious Diseases,
vol. 8,
no. 11,
pp. ofab509,
Okt.
2021.
| DOI: | 10.1093/ofid/ofab509 |
| Datei: | https://doi.org/10.1093/ofid/ofab509 |
[de]
L. Lohner,
D. Fröb,
C. Edler,
A. S. Schröder,
E. Dietz and
B. Ondruschka,
"SARS-CoV-2-assoziierte Todesfälle von erwachsenen Personen bis 50 Jahre",
Rechtsmedizin,
vol. 31,
no. 5,
pp. 418—426,
Okt.
2021.
| DOI: | 10.1007/s00194-021-00483-8 |
| Datei: | https://doi.org/10.1007/s00194-021-00483-8 |
[de]
A. Klein,
F. Langenwalder,
F. Heinrich,
K. Meißner,
A. S. Schröder,
K. Püschel,
B. Ondruschka,
M. Lütgehetmann and
A. Heinemann,
"SARS-CoV‑2-Zufallsentdeckungen bei Hamburger Todesfällen: ein epidemiologisches Monitoring während des dynamischen Infektionsgeschehens im Frühjahr 2020",
Rechtsmedizin,
vol. 31,
no. 5,
pp. 427—433,
Okt.
2021.
| DOI: | 10.1007/s00194-021-00481-w |
| Datei: | https://doi.org/10.1007/s00194-021-00481-w |
A. Surov,
M. Akritidou,
A. G. Bach,
N. Bailis,
M. Lerche,
H. J. Meyer,
M. Pech and
A. Wienke,
"A New Index for the Prediction of 30-Day Mortality in Patients With Pulmonary Embolism: The Pulmonary Embolism Mortality Score (PEMS)",
Angiology,
vol. 72,
no. 8,
pp. 787-793,
Sep.
2021.
Abstract:
Our aim was to analyze possibility of combination of basic clinical and radiological signs to predict 30-day mortality after acute pulmonary embolism (PE). We included 486 patients. Age, gender, simplified pulmonary embolism index (sPESI), pH, troponin, N-terminal natriuretic peptide, minimal systolic and diastolic blood pressure, O2 saturation, syncope, need for vasopressors, thrombotic obstruction, vessel diameter, short axis ratio right ventricle/left ventricle, and contrast medium reflux into the inferior vena cava (IVC) were analyzed. A backward algorithm in a logistic regression model was used to identify relevant risk factors. Multiple logistic regression analysis identified that sPESI, pH, minimal diastolic blood pressure, IVC reflux, and need for vasopressors influenced 30-day mortality. A score for mortality prediction was constructed (the Pulmonary Embolism Mortality Score): sPESI >2 points (1 point), pH <7.35 (1 point), minimal diastolic blood pressure <45 mm Hg (1 point), IVC reflux (1 point), and need for vasopressors (2 points). Patients with >3 points showed higher 30-day mortality (sensitivity: 84.9%, specificity: 83.0%, positive predictive value: 51.8%, negative predictive value: 96.2%). The net reclassification improvement compared with the sPESI was 0.94 (95% CI = 0.73-1.15). In conclusion, a new score can predict 30-day mortality in patients with PE and is more sensitive than sPESI.
| DOI: | 10.1177/0003319721993346 |
| Datei: | https://pubmed.ncbi.nlm.nih.gov/33557585/ |
Abstract:
Our aim was to analyze possibility of combination of basic clinical and radiological signs to predict 30-day mortality after acute pulmonary embolism (PE). We included 486 patients. Age, gender, simplified pulmonary embolism index (sPESI), pH, troponin, N-terminal natriuretic peptide, minimal systolic and diastolic blood pressure, O2 saturation, syncope, need for vasopressors, thrombotic obstruction, vessel diameter, short axis ratio right ventricle/left ventricle, and contrast medium reflux into the inferior vena cava (IVC) were analyzed. A backward algorithm in a logistic regression model was used to identify relevant risk factors. Multiple logistic regression analysis identified that sPESI, pH, minimal diastolic blood pressure, IVC reflux, and need for vasopressors influenced 30-day mortality. A score for mortality prediction was constructed (the Pulmonary Embolism Mortality Score): sPESI >2 points (1 point), pH <7.35 (1 point), minimal diastolic blood pressure <45 mm Hg (1 point), IVC reflux (1 point), and need for vasopressors (2 points). Patients with >3 points showed higher 30-day mortality (sensitivity: 84.9%, specificity: 83.0%, positive predictive value: 51.8%, negative predictive value: 96.2%). The net reclassification improvement compared with the sPESI was 0.94 (95% CI = 0.73-1.15). In conclusion, a new score can predict 30-day mortality in patients with PE and is more sensitive than sPESI.
M. Sähn,
C. Yüksel,
S. Keil,
M. P. Zeisberger,
M. Post,
M. Kleines,
J. C. Brokmann,
C. Hübel,
C. K. Kuhl,
P. Isfort and
M. F. Schulze-Hagen,
"Accuracy of Chest CT for Differentiating COVID-19 from COVID-19 Mimics",
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
vol. 193,
no. 9,
pp. 1081-1091,
Sep.
2021.
Abstract:
To determine the performance of radiologists with different levels of expertise regarding the differentiation of COVID-19 from other atypical pneumonias. Chest CT to identify patients suffering from COVID-19 has been reported to be limited by its low specificity for distinguishing COVID-19 from other atypical pneumonias ("COVID-19 mimics"). Meanwhile, the understanding of the morphologic patterns of COVID-19 has improved and they appear to be fairly specific. Between 02/2020 and 04/2020, 60 patients with COVID-19 pneumonia underwent chest CT in our department. Cases were matched with a comparable control group of 60 patients of similar age, sex, and comorbidities, who underwent chest CT prior to 01/2020 for atypical pneumonia caused by other pathogens. Included were other viral, fungal, and bacterial pathogens. All 120 cases were blinded to patient history and were reviewed independently by two radiologists and two radiology residents. Readers rated the probability of COVID-19 pneumonia according to the COV-RADS classification system. Results were analyzed using Clopper-Pearson 95 % confidence intervals, Youden's Index for test quality criteria, and Fleiss' kappa statistics. Overall, readers were able to correctly identify the presence of COVID-19 pneumonia in 219/240 (sensitivity: 91 %; 95 %-CI; 86.9 %-94.5 %), and to correctly attribute CT findings to COVID-19 mimics in 159/240 ratings (specificity: 66.3 %; 59.9 %-72.2 %), yielding an overall diagnostic accuracy of 78.8 % (378/480; 74.8 %-82.3 %). Individual reader accuracy ranged from 74.2 % (89/120) to 84.2 % (101/120) and did not correlate significantly with reader expertise. Youden's Index was 0.57. Between-reader agreement was moderate (κ = 0.53). In this enriched cohort, radiologists were able to distinguish COVID-19 from "COVID-19 mimics" with moderate diagnostic accuracy. Accuracy did not correlate with reader expertise. · In a scenario of direct comparison (no negative findings), CT allows the differentiation of COVID-19 from other atypical pneumonias ("COVID mimics") with moderate accuracy.. · Reader expertise did not significantly influence these results.. · Despite similar patterns and distributions of pulmonary findings, radiologists were able to estimate the probability of COVID-19 pneumonia using the COV-RADS classification in a standardized manner in the larger proportion of cases.. · Sähn M, Yüksel C, Keil S et al. Accuracy of Chest CT for Differentiating COVID-19 from COVID-19 Mimics. Fortschr Röntgenstr 2021; 193: 1081 - 1091.
| DOI: | 10.1055/a-1388-7950 |
| Datei: | https://pubmed.ncbi.nlm.nih.gov/33772486/ |
Abstract:
To determine the performance of radiologists with different levels of expertise regarding the differentiation of COVID-19 from other atypical pneumonias. Chest CT to identify patients suffering from COVID-19 has been reported to be limited by its low specificity for distinguishing COVID-19 from other atypical pneumonias ("COVID-19 mimics"). Meanwhile, the understanding of the morphologic patterns of COVID-19 has improved and they appear to be fairly specific. Between 02/2020 and 04/2020, 60 patients with COVID-19 pneumonia underwent chest CT in our department. Cases were matched with a comparable control group of 60 patients of similar age, sex, and comorbidities, who underwent chest CT prior to 01/2020 for atypical pneumonia caused by other pathogens. Included were other viral, fungal, and bacterial pathogens. All 120 cases were blinded to patient history and were reviewed independently by two radiologists and two radiology residents. Readers rated the probability of COVID-19 pneumonia according to the COV-RADS classification system. Results were analyzed using Clopper-Pearson 95 % confidence intervals, Youden's Index for test quality criteria, and Fleiss' kappa statistics. Overall, readers were able to correctly identify the presence of COVID-19 pneumonia in 219/240 (sensitivity: 91 %; 95 %-CI; 86.9 %-94.5 %), and to correctly attribute CT findings to COVID-19 mimics in 159/240 ratings (specificity: 66.3 %; 59.9 %-72.2 %), yielding an overall diagnostic accuracy of 78.8 % (378/480; 74.8 %-82.3 %). Individual reader accuracy ranged from 74.2 % (89/120) to 84.2 % (101/120) and did not correlate significantly with reader expertise. Youden's Index was 0.57. Between-reader agreement was moderate (κ = 0.53). In this enriched cohort, radiologists were able to distinguish COVID-19 from "COVID-19 mimics" with moderate diagnostic accuracy. Accuracy did not correlate with reader expertise. · In a scenario of direct comparison (no negative findings), CT allows the differentiation of COVID-19 from other atypical pneumonias ("COVID mimics") with moderate accuracy.. · Reader expertise did not significantly influence these results.. · Despite similar patterns and distributions of pulmonary findings, radiologists were able to estimate the probability of COVID-19 pneumonia using the COV-RADS classification in a standardized manner in the larger proportion of cases.. · Sähn M, Yüksel C, Keil S et al. Accuracy of Chest CT for Differentiating COVID-19 from COVID-19 Mimics. Fortschr Röntgenstr 2021; 193: 1081 - 1091.
J. Ihlow,
A. Seelhoff,
V. M. Corman,
A. D. Gruber,
S. Dökel,
J. Meinhardt,
H. Radbruch,
E. Späth-Schwalbe,
S. Elezkurtaj,
D. Horst and
H. Herbst,
"COVID-19: a fatal case of acute liver failure associated with SARS-CoV-2 infection in pre-existing liver cirrhosis",
BMC Infectious Diseases,
vol. 21,
no. 1,
pp. 901,
Sep.
2021.
| DOI: | 10.1186/s12879-021-06605-7 |
| Datei: | https://doi.org/10.1186/s12879-021-06605-7 |
M. Metzendorf,
"Das Cochrane COVID-19 Studienregister – eine studienbasierte, strukturierte Datenbank zur effizienten Identifizierung wissenschaftlicher Evidenz",
GMS Med Bibl Inf,
vol. 21,
no. 1-2,
pp. Doc09,
Sep.
2021.
| DOI: | 10.3205/mbi000498 |
A. Fitzek,
J. Schädler,
E. Dietz,
A. Ron,
M. Gerling,
A. Kammal,
L. Lohner,
C. Falck,
D. Möbius,
H. Goebels,
A. Gerberding,
A. Schröder,
J. Sperhake,
A. Klein,
D. Fröb,
H. Mushumba,
S. Wilmes,
I. Kniep,
F. Heinrich,
F. Langenwalder,
K. Meißner,
P. Lange,
A. Zapf,
K. Püschel,
A. Heinemann,
M. Glatzel,
J. Matschke,
M. Lütgehetmann,
S. Steurer,
C. Thorns,
C. Edler and
B. Ondruschka,
"Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death cases",
Sci Rep,
vol. 11,
no. 1,
pp. 19342,
Sep.
2021.
| DOI: | 10.1038/s41598-021-98499-3 |
[en]
A. Fitzek,
J. Schädler,
E. Dietz,
A. Ron,
M. Gerling,
A. L. Kammal,
L. Lohner,
C. Falck,
D. Möbius,
H. Goebels,
A. Gerberding,
A. S. Schröder,
J. Sperhake,
A. Klein,
D. Fröb,
H. Mushumba,
S. Wilmes,
S. Anders,
I. Kniep,
F. Heinrich,
F. Langenwalder,
K. Meißner,
P. Lange,
A. Zapf,
K. Püschel,
A. Heinemann,
M. Glatzel,
J. Matschke,
M. Aepfelbacher,
M. Lütgehetmann,
S. Steurer,
C. Thorns,
C. Edler and
B. Ondruschka,
"Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death cases",
Scientific Reports,
vol. 11,
no. 1,
pp. 19342,
Sep.
2021.
Nature Publishing Group.
Abstract:
Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic with significant mortality. Accurate information on the specific circumstances of death and whether patients died from or with SARS-CoV-2 is scarce. To distinguish COVID-19 from non-COVID-19 deaths, we performed a systematic review of 735 SARS-CoV-2-associated deaths in Hamburg, Germany, from March to December 2020, using conventional autopsy, ultrasound-guided minimally invasive autopsy, postmortem computed tomography and medical records. Statistical analyses including multiple logistic regression were used to compare both cohorts. 84.1% (n = 618) were classified as COVID-19 deaths, 6.4% (n = 47) as non-COVID-19 deaths, 9.5% (n = 70) remained unclear. Median age of COVID-19 deaths was 83.0 years, 54.4% were male. In the autopsy group (n = 283), the majority died of pneumonia and/or diffuse alveolar damage (73.6%; n = 187). Thromboses were found in 39.2% (n = 62/158 cases), pulmonary embolism in 22.1% (n = 56/253 cases). In 2020, annual mortality in Hamburg was about 5.5% higher than in the previous 20 years, of which 3.4% (n = 618) represented COVID-19 deaths. Our study highlights the need for mortality surveillance and postmortem examinations. The vast majority of individuals who died directly from SARS-CoV-2 infection were of advanced age and had multiple comorbidities.
| DOI: | 10.1038/s41598-021-98499-3 |
| Datei: | https://www.nature.com/articles/s41598-021-98499-3 |
Abstract:
Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic with significant mortality. Accurate information on the specific circumstances of death and whether patients died from or with SARS-CoV-2 is scarce. To distinguish COVID-19 from non-COVID-19 deaths, we performed a systematic review of 735 SARS-CoV-2-associated deaths in Hamburg, Germany, from March to December 2020, using conventional autopsy, ultrasound-guided minimally invasive autopsy, postmortem computed tomography and medical records. Statistical analyses including multiple logistic regression were used to compare both cohorts. 84.1% (n = 618) were classified as COVID-19 deaths, 6.4% (n = 47) as non-COVID-19 deaths, 9.5% (n = 70) remained unclear. Median age of COVID-19 deaths was 83.0 years, 54.4% were male. In the autopsy group (n = 283), the majority died of pneumonia and/or diffuse alveolar damage (73.6%; n = 187). Thromboses were found in 39.2% (n = 62/158 cases), pulmonary embolism in 22.1% (n = 56/253 cases). In 2020, annual mortality in Hamburg was about 5.5% higher than in the previous 20 years, of which 3.4% (n = 618) represented COVID-19 deaths. Our study highlights the need for mortality surveillance and postmortem examinations. The vast majority of individuals who died directly from SARS-CoV-2 infection were of advanced age and had multiple comorbidities.
[en]
A. S. Schröder,
C. Edler,
B. Ondruschka,
K. Püschel,
J. Schädler,
A. Heinemann,
F. Heinrich,
M. Lütgehetmann,
S. Pfefferle,
M. Aepfelbacher,
A. Fitzek and
J. Sperhake,
"The handling of SARS-CoV-2 associated deaths - infectivity of the body",
Forensic Science, Medicine and Pathology,
vol. 17,
no. 3,
pp. 411—418,
Sep.
2021.
| DOI: | 10.1007/s12024-021-00379-9 |
| Datei: | https://doi.org/10.1007/s12024-021-00379-9 |
P. Möller,
G. Uzun,
A. Singh,
A. Beck,
M. Bettag,
H. Bösmüller,
M. Guthoff,
F. Dorn,
G. C. Petzold,
H. Henkes,
N. Heyne,
H. Jumaa,
K. Kreiser,
C. Limpach,
B. Luz,
M. Maschke,
J. Müller,
J. Münch,
S. Nagel,
B. Pötzsch,
J. Müller,
C. Schlegel,
A. Viardot,
H. Bäzner,
M. Wolf,
L. Pelzl,
V. Warm,
W. A. Willinek,
J. Steiner,
N. Schneiderhan-Marra,
D. Vollherbst,
U. J. Sachs,
F. Fend and
T. Bakchoul,
"Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia",
Haematologica,
vol. 106,
no. 8,
pp. 2170-2179,
Aug.
2021.
| DOI: | 10.3324/haematol.2021.279000 |
T. Aschman,
J. Schneider,
S. Greuel,
J. Meinhardt,
S. Streit,
H. Goebel,
I. Büttnerova,
S. Elezkurtaj,
F. Scheibe,
J. Radke,
C. Meisel,
C. Drosten,
H. Radbruch,
F. Heppner,
V. Corman and
W. Stenzel,
"Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died",
JAMA Neurol,
vol. 78,
no. 8,
pp. 948-960,
Aug.
2021.
| DOI: | 10.1001/jamaneurol.2021.2004 |
T. Aschman,
J. Schneider,
S. Greuel,
J. Meinhardt,
S. Streit,
H. Goebel,
I. Büttnerova,
S. Elezkurtaj,
F. Scheibe,
J. Radke,
C. Meisel,
C. Drosten,
H. Radbruch,
F. L. Heppner,
V. M. Corman and
W. Stenzel,
"Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died",
JAMA Neurology,
vol. 78,
no. 8,
pp. 948—960,
Aug.
2021.
| DOI: | 10.1001/jamaneurol.2021.2004 |
| Datei: | https://doi.org/10.1001/jamaneurol.2021.2004 |
[en]
D. Nörz,
M. Grunwald,
F. Olearo,
N. Fischer,
M. Aepfelbacher,
S. Pfefferle and
M. Lütgehetmann,
"Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR assay with built-in screening functionality for del-HV69/70- and N501Y variants such as B.1.1.7",
Journal of Clinical Virology,
vol. 141,
pp. 104894,
Aug.
2021.
Abstract:
.
| DOI: | 10.1016/j.jcv.2021.104894 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S138665322100161X |
Abstract:
.
[en]
J. M. Kruse,
D. Zickler,
W. M. Lüdemann,
S. K. Piper,
I. Gotthardt,
J. Ihlow,
S. Greuel,
D. Horst,
A. Kahl,
K. Eckardt and
S. Elezkurtaj,
"Evidence for a thromboembolic pathogenesis of lung cavitations in severely ill COVID-19 patients",
Scientific Reports,
vol. 11,
no. 1,
pp. 16039,
Aug.
2021.
| DOI: | 10.1038/s41598-021-95694-0 |
| Datei: | https://www.nature.com/articles/s41598-021-95694-0 |
[en]
B. Kaltschmidt,
A. D. E. Fitzek,
J. Schaedler,
C. Förster,
C. Kaltschmidt,
T. Hansen,
F. Steinfurth,
B. A. Windmöller,
C. Pilger,
C. Kong,
K. Singh,
A. Nierhaus,
D. Wichmann,
J. Sperhake,
K. Püschel,
T. Huser,
M. Krüger,
S. C. Robson,
L. Wilkens and
J. Esch,
"Hepatic Vasculopathy and Regenerative Responses of the Liver in Fatal Cases of COVID-19",
Clinical Gastroenterology and Hepatology,
vol. 19,
no. 8,
pp. 1726—1729.e3,
Aug.
2021.
| DOI: | 10.1016/j.cgh.2021.01.044 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S154235652100094X |
M. Ricke-Hoch,
E. Stelling,
L. Lasswitz,
A. Gunesch,
M. Kasten,
F. Zapatero-Belinchón,
G. Brogden,
G. Gerold,
T. Pietschmann,
V. Montiel,
J. Balligand,
F. Facciotti,
E. Hirsch,
T. Gausepohl,
H. Elbahesh,
G. Rimmelzwaan,
A. Höfer,
M. Kühnel,
D. Jonigk,
J. Eigendorf,
U. Tegtbur,
L. Mink,
M. Scherr,
T. Illig,
A. Schambach,
T. Pfeffer,
A. Hilfiker,
A. Haverich and
D. Hilfiker-Kleiner,
"Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease",
PLoS One,
vol. 16,
no. 8,
pp. e0255335,
Aug.
2021.
| DOI: | 10.1371/journal.pone.0255335 |
[en]
D. Simnica,
C. Schultheiß,
M. Mohme,
L. Paschold,
E. Willscher,
A. Fitzek,
K. Püschel,
J. Matschke,
S. Ciesek,
D. G. Sedding,
Y. Zhao,
N. Gagliani,
Y. Maringer,
J. S. Walz,
J. Heide,
J. Schulze-zur-Wiesch and
M. Binder,
"Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohorts",
Clinical & Translational Immunology,
vol. 10,
no. 9,
pp. e1340,
Aug.
2021.
| DOI: | 10.1002/cti2.1340 |
| Datei: | https://onlinelibrary.wiley.com/doi/abs/10.1002/cti2.1340 |
M. Kahn,
L. Schuierer,
C. Bartenschlager,
S. Zellmer,
R. Frey,
M. Freitag,
C. Dhillon,
M. Heier,
A. Ebigbo,
C. Denzel,
S. Temizel,
H. Messmann,
M. Wehler,
R. Hoffmann,
E. Kling and
C. Römmele,
"Performance of antigen testing for diagnosis of COVID-19: a direct comparison of a lateral flow device to nucleic acid amplification based tests",
BMC Infectious Diseases,
vol. 21,
no. 1,
pp. 798,
Aug.
2021.
| DOI: | 10.1186/s12879-021-06524-7 |
| Datei: | https://doi.org/10.1186/s12879-021-06524-7 |
T. S. Boender,
W. Cai,
M. Schranz and
D. Stahl,
"Using routine emergency department data for syndromic surveillance of acute respiratory illness before and during the COVID-19 pandemic in Germany, week 10-2017 and 10-2021",
medRxiv,
Aug.
2021.
| DOI: | 10.1101/2021.08.19.21262303 |
S. Dickel,
C. Grimm,
M. Popp,
C. Struwe,
A. Sachkova,
M. Golinski,
C. Seeber,
F. Fichtner,
D. Heise,
P. Kranke,
W. Meissner,
S. Laudi,
S. Voigt-Radloff,
J. Meerpohl,
O. Moerer and
Group On Behalf Of The German CEOsys Study,
"A Nationwide Cross-Sectional Online Survey on the Treatment of COVID-19-ARDS: High Variance in Standard of Care in German ICUs",
J Clin Med,
vol. 10,
no. 15,
pp. 3363,
Jul.
2021.
| DOI: | 10.3390/jcm10153363 |
C. Holzmann-Littig,
M. C. Braunisch,
P. Kranke,
M. Popp,
C. Seeber,
F. Fichtner,
B. Littig,
J. Carbajo-Lozoya,
T. Frank,
J. Meerpohl,
B. Haller and
C. Schmaderer,
"COVID-19 Vaccination Acceptance and Hesitancy among Healthcare Workers in Germany",
Vaccines (Basel),
vol. 9,
no. 7,
pp. 777,
Jul.
2021.
| DOI: | 10.3390/vaccines9070777 |
[en]
K. Evert,
T. Dienemann,
C. Brochhausen,
D. Lunz,
M. Lubnow,
M. Ritzka,
F. Keil,
M. Trummer,
A. Scheiter,
B. Salzberger,
U. Reischl,
P. Boor,
A. Gessner,
J. Jantsch,
D. F. Calvisi,
M. Evert,
B. Schmidt and
M. Simon,
"Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation",
Virchows Archiv,
vol. 479,
no. 1,
pp. 97—108,
Jul.
2021.
Abstract:
Between April and June 2020, i.e., during the first wave of pandemic coronavirus disease 2019 (COVID-19), 55 patients underwent long-term treatment in the intensive care unit at the University Hospital of Regensburg. Most of them were transferred from smaller hospitals, often due to the need for an extracorporeal membrane oxygenation system. Autopsy was performed in 8/17 COVID-19-proven patients after long-term treatment (mean: 33.6 days). Autopsy revealed that the typical pathological changes occurring during the early stages of the disease (e.g., thrombosis, endothelitis, capillaritis) are less prevalent at this stage, while severe diffuse alveolar damage and especially coinfection with different fungal species were the most conspicuous finding. In addition, signs of macrophage activation syndrome was detected in 7 of 8 patients. Thus, fungal infections were a leading cause of death in our cohort of severely ill patients and may alter clinical management of patients, particularly in long-term periods of treatment.
| DOI: | 10.1007/s00428-020-03014-0 |
| Datei: | https://doi.org/10.1007/s00428-020-03014-0 |
Abstract:
Between April and June 2020, i.e., during the first wave of pandemic coronavirus disease 2019 (COVID-19), 55 patients underwent long-term treatment in the intensive care unit at the University Hospital of Regensburg. Most of them were transferred from smaller hospitals, often due to the need for an extracorporeal membrane oxygenation system. Autopsy was performed in 8/17 COVID-19-proven patients after long-term treatment (mean: 33.6 days). Autopsy revealed that the typical pathological changes occurring during the early stages of the disease (e.g., thrombosis, endothelitis, capillaritis) are less prevalent at this stage, while severe diffuse alveolar damage and especially coinfection with different fungal species were the most conspicuous finding. In addition, signs of macrophage activation syndrome was detected in 7 of 8 patients. Thus, fungal infections were a leading cause of death in our cohort of severely ill patients and may alter clinical management of patients, particularly in long-term periods of treatment.
[en]
S. Greuel,
J. Ihlow,
M. Dragomir,
S. Streit,
V. M. Corman,
L. Haberbosch,
D. Winkler,
J. Meinhardt,
T. Aschman,
J. Schneider,
I. Trotsyuk,
C. A. Kunze,
L. Maurer,
H. Radbruch,
F. L. Heppner,
D. Horst and
S. Elezkurtaj,
"COVID-19: Autopsy findings in six patients between 26 and 46 years of age",
International Journal of Infectious Diseases,
vol. 108,
pp. 274—281,
Jul.
2021.
| DOI: | 10.1016/j.ijid.2021.05.069 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S1201971221004720 |
C. Edler,
A. Klein,
A. Schröder,
J. Sperhake and
B. Ondruschka,
"Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®)",
Leg Med (Tokyo),
vol. 51,
pp. 101895,
Jul.
2021.
| DOI: | 10.1016/j.legalmed.2021.101895 |
[en]
C. Edler,
A. Klein,
A. S. Schröder,
J. Sperhake and
B. Ondruschka,
"Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®)",
Legal Medicine,
vol. 51,
pp. 101895,
Jul.
2021.
| DOI: | 10.1016/j.legalmed.2021.101895 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S1344622321000596 |
[en]
M. Schwabenland,
H. Salié,
J. Tanevski,
S. Killmer,
M. S. Lago,
A. E. Schlaak,
L. Mayer,
J. Matschke,
K. Püschel,
A. Fitzek,
B. Ondruschka,
H. E. Mei,
T. Boettler,
C. Neumann-Haefelin,
M. Hofmann,
A. Breithaupt,
N. Genc,
C. Stadelmann,
J. Saez-Rodriguez,
P. Bronsert,
K. Knobeloch,
T. Blank,
R. Thimme,
M. Glatzel,
M. Prinz and
B. Bengsch,
"Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions",
Immunity,
vol. 54,
no. 7,
pp. 1594—1610.e11,
Jul.
2021.
| DOI: | 10.1016/j.immuni.2021.06.002 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S1074761321002466 |